Squarepoint’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.28M | Sell |
54,134
-435,340
| -89% | -$25.4M | ﹤0.01% | 1817 |
|
|
2025
Q4 | $26.4M | Sell |
489,474
-359,471
| -42% | -$17.3M | 0.03% | 614 |
|
|
2025
Q3 | $38.3M | Sell |
848,945
-1,223,585
| -59% | -$57.1M | 0.04% | 494 |
|
|
2025
Q2 | $95.9M | Buy |
2,072,530
+1,971,136
| +1,944% | +$96.8M | 0.1% | 218 |
|
|
2025
Q1 | $6.18M | Sell |
101,394
-111,617
| -52% | -$6.51M | 0.01% | 1300 |
|
|
2024
Q4 | $12M | Buy |
213,011
+158,427
| +290% | +$8.85M | 0.01% | 1048 |
|
|
2024
Q3 | $2.82M | Sell |
54,584
-3,914,635
| -99% | -$184M | ﹤0.01% | 1822 |
|
|
2024
Q2 | $165M | Buy |
3,969,219
+3,435,412
| +644% | +$154M | 0.27% | 50 |
|
|
2024
Q1 | $28.9M | Sell |
533,807
-3,055,428
| -85% | -$156M | 0.05% | 458 |
|
|
2023
Q4 | $184M | Buy |
3,589,235
+2,648,965
| +282% | +$139M | 0.35% | 39 |
|
|
2023
Q3 | $54.6M | Sell |
940,270
-50,769
| -5% | -$3.11M | 0.13% | 149 |
|
|
2023
Q2 | $63.4M | Buy |
991,039
+970,996
| +4,845% | +$65.1M | 0.19% | 98 |
|
|
2023
Q1 | $1.39M | Sell |
20,043
-843,730
| -98% | -$59.5M | 0.01% | 1673 |
|
|
2022
Q4 | $62.1M | Buy |
863,773
+702,166
| +434% | +$52.9M | 0.25% | 66 |
|
|
2022
Q3 | $11.5M | Sell |
161,607
-301,847
| -65% | -$21.9M | 0.06% | 379 |
|
|
2022
Q2 | $35.7M | Buy |
463,454
+199,065
| +75% | +$15.2M | 0.2% | 110 |
|
|
2022
Q1 | $19.3M | Sell |
264,389
-525,780
| -67% | -$35.3M | 0.08% | 248 |
|
|
2021
Q4 | $49.3M | Buy |
790,169
+193,153
| +32% | +$11.3M | 0.13% | 133 |
|
|
2021
Q3 | $35.3M | Buy |
597,016
+311,549
| +109% | +$20.5M | 0.1% | 195 |
|
|
2021
Q2 | $19.1M | Sell |
285,467
-391,215
| -58% | -$25.5M | 0.07% | 246 |
|
|
2021
Q1 | $42.7M | Buy |
676,682
+296,107
| +78% | +$18.4M | 0.25% | 64 |
|
|
2020
Q4 | $23.6M | Sell |
380,575
-91,859
| -19% | -$5.65M | 0.18% | 97 |
|
|
2020
Q3 | $28.5M | Sell |
472,434
-93,159
| -16% | -$5.61M | 0.38% | 38 |
|
|
2020
Q2 | $33.3M | Buy |
565,593
+396,192
| +234% | +$23.7M | 0.54% | 14 |
|
|
2020
Q1 | $9.44M | Buy |
169,401
+60,701
| +56% | +$3.71M | 0.24% | 90 |
|
|
2019
Q4 | $6.98M | Buy |
+108,700
| New | +$6.23M | 0.04% | 396 |
|
|
2019
Q3 | – | Sell |
-51,503
| Closed | -$2.42M | – | 2354 |
|
|
2019
Q2 | $2.34M | Sell |
51,503
-632,824
| -92% | -$29.5M | 0.02% | 758 |
|
|
2019
Q1 | $32.6M | Buy |
684,327
+567,427
| +485% | +$28.3M | 0.35% | 53 |
|
|
2018
Q4 | $6.08M | Sell |
116,900
-37,759
| -24% | -$2.03M | 0.07% | 358 |
|
|
2018
Q3 | $9.6M | Buy |
154,659
+56,759
| +58% | +$3.37M | 0.11% | 237 |
|
|
2018
Q2 | $5.42M | Sell |
97,900
-29,703
| -23% | -$1.6M | 0.07% | 381 |
|
|
2018
Q1 | $8.07M | Sell |
127,603
-136,418
| -52% | -$8.78M | 0.13% | 210 |
|
|
2017
Q4 | $16.2M | Buy |
+264,021
| New | +$16.5M | 0.28% | 61 |
|
|
2017
Q3 | – | Sell |
-354,520
| Closed | -$19.8M | – | 1620 |
|
|
2017
Q2 | $19.8M | Buy |
354,520
+275,078
| +346% | +$15M | 0.39% | 40 |
|
|
2017
Q1 | $4.32M | Buy |
+79,442
| New | +$4.36M | 0.12% | 211 |
|
|
2016
Q4 | – | Sell |
-338,018
| Closed | -$18.2M | – | 1771 |
|
|
2016
Q3 | $18.2M | Buy |
338,018
+333,570
| +7,499% | +$21.4M | 1.21% | 5 |
|
|
2016
Q2 | $327K | Sell |
4,448
-2,491
| -36% | -$176K | 0.02% | 693 |
|
|
2016
Q1 | $443K | Buy |
+6,939
| New | +$438K | 0.03% | 672 |
|
|
2015
Q2 | – | Sell |
-7,427
| Closed | -$479K | – | 470 |
|
|
2015
Q1 | $479K | Buy |
+7,427
| New | +$465K | 0.17% | 195 |
|
Other funds holding BMY
VCM
VPM
Squarepoint's BMY Position: Q1 2026 in Review
Squarepoint reduced its Bristol-Myers Squibb (BMY) stake by 89% in Q1 2026, selling an estimated $25.4M and leaving 54,134 shares worth $3.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1817.
Squarepoint first reported a position in BMY in Q1 2015 and has held it in 39 quarters since. The position peaked at $184M in Q4 2023. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Squarepoint held 54,134 shares of Bristol-Myers Squibb worth $3.28M as of Q1 2026.
- Squarepoint sold 435,340 Bristol-Myers Squibb shares in Q1 2026, an estimated $25.4M.
- Bristol-Myers Squibb made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1817 holding.
- Squarepoint first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 39 quarters since.
- Squarepoint's Bristol-Myers Squibb position peaked at $184M in Q4 2023.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.